

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



KINGWORLD MEDICINES GROUP LIMITED
金活醫藥集團有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code : 01110)

INSIDE INFORMATION ANNOUNCEMENT

**TERMINATION OF
THE MEMORANDUM OF UNDERSTANDING
IN RELATION TO THE PROPOSED ACQUISITION**

This announcement is made by Kingworld Medicines Group Limited (the “**Company**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the laws of Hong Kong).

Reference is made to the announcement of the Company dated 22 January 2026 (the “**Announcement**”) in relation to the memorandum of understanding dated 22 January 2026 (the “**MOU**”) entered into among Kingworld Medicine and Healthcare Group Limited (金活醫藥保健集團有限公司) (“**Kingworld Medicine (BVI)**”), a wholly-owned subsidiary of the Company, the intended vendor (the “**Intended Vendor**”) and the guarantors in respect of a proposed acquisition of the entire issued share capital of the target company (the “**Target Company**”).

TERMINATION OF THE MOU

The board of directors of the Company (the “**Board**”) announces that Kingworld Medicine (BVI) has exercised its right to terminate the MOU with immediate effect on 15 June 2026, in accordance with the terms of the MOU.

Kingworld Medicine (BVI) has requested the Intended Vendor to return the deposit in the amount of HK\$3,321,840 in full within five (5) business days from the date of termination of the MOU (being, 15 June 2026).

The Board considers that the termination of the MOU does not have any material adverse effect on the existing financial position and operations of the Group.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Kingworld Medicines Group Limited
Zhao Li Sheng
Chairman

Hong Kong, 15 June 2026

As at the date of this announcement, the executive Directors are Mr. Zhao Li Sheng, Ms. Chan Lok San and Mr. Zhou Xuhua, and the independent non-executive Directors are Mr. Duan Jidong, Mr. Wong Cheuk Lam and Dr. Chu Xiaoping.